{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:16:36Z","timestamp":1791486996188,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clml.2015.09.008","type":"journal-article","created":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T13:28:50Z","timestamp":1443878930000},"page":"797-802.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines"],"prefix":"10.1016","volume":"15","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Makenbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lingohr-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.09.008_bib1","first-page":"205","article-title":"Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia","volume":"3","author":"Ramchandren","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.clml.2015.09.008_bib2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.09.008_bib3","series-title":"Chronic myelogenous leukemia","year":"2014"},{"key":"10.1016\/j.clml.2015.09.008_bib4","series-title":"FDA approves new orphan drug for chronic myelogenous leukemia","year":"2012"},{"key":"10.1016\/j.clml.2015.09.008_bib5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.008_bib6","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.008_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.clml.2015.09.008_bib8","series-title":"Sprycel","year":"2015"},{"key":"10.1016\/j.clml.2015.09.008_bib9","series-title":"Tasigna","year":"2015"},{"key":"10.1016\/j.clml.2015.09.008_bib10","first-page":"1","article-title":"Summary health statistics for US adults: national health interview survey, 2012","volume":"10","author":"Blackwell","year":"2014","journal-title":"Vital Health Stat"},{"key":"10.1016\/j.clml.2015.09.008_bib11","first-page":"1854","article-title":"Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions","volume":"14","author":"Fried","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2015.09.008_bib12","series-title":"Improving prescription medicine adherence is key to better health care","year":"2011"},{"key":"10.1016\/j.clml.2015.09.008_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3121\/cmr.2013.1113","article-title":"Patient characteristics associated with medication adherence","volume":"11","author":"Rolnick","year":"2013","journal-title":"Clin Med Res"},{"key":"10.1016\/j.clml.2015.09.008_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2013.11.002","article-title":"Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukemia elderly patients","volume":"25","author":"Iurlo","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clml.2015.09.008_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.leukres.2014.06.020","article-title":"Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival","volume":"38","author":"Breccia","year":"2014","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:57Z","timestamp":1761870417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015012963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S2152265015012963"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}